menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Novartis loses latest bid to block generic version of blockbuster heart drug

    REUTERS

    USV launches heart failure medication at 8rs per 50mg tablet

    EXPRESSPHARMA

    Novartis loses initial bid to block generic of best-selling heart drug

    REUTERS

    Zydus Life hits 52-week high on USFDA nod for Sacubitril and Valsartan

    ECONOMIC TIMES

    Zydus Pharms Generic Sacubitril :Valsartan Receives Approval in US

    FDA

    Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin

    PRESS RELEASE

    USDMF for Sacubitril Sodium has been submitted With An Innovative Devp Strategy

    PRESS RELEASE

    Novartis heart drug price may fall by 60% on generic rollouts

    ECONOMIC TIMES

    Dr Reddy`s cuts price of cardiovascular drug Cidmus

    ECONOMIC TIMES

    HC reserves order on Natco`s plea over patent for Novartis drug

    ECONOMIC TIMES

    Top Novartis cardiac drug to go off patent

    ECONOMICTIMES

    Novartis files FDA appeal in bid to block Entresto generics

    FIERCEPHARMA

    Delhi HC restrains generic firms from making, selling patent drug of Novartis

    ECONOMICTIMES

    Novartis Entresto® indicated for treatment of hypertension in China

    PRESS RELEASE

    Sacubitril/valsartan not superior to valsartan alone in advanced HFrEF: LIFE

    HEALIO

    Novartis whiffs on Entresto study after heart attacks that doesn`t going down

    ENDPTS

    Novartis` Entresto came up short in a post-heart attack phase 3

    FIERCEPHARMA

    FDA reviewers argue for Novartis ahead of Entresto advisory panel confab

    FIERCEPHARMA

    Cosentyx, Entresto drive topline growth for Novartis in Q4

    PMLIVE

    Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

    PR NEWSWIRE

    Novartis` Entresto falls short at Ph 3 in heart failure with preserved ejection

    PHARMAFILE

    Novartis exercises option for RNA-targeting drug candidate

    IN-PHARMATECHNOLOGIST

    Novartis expects a parade to blockbusterland, with Entresto leading the way

    FIERCE PHARMA

    Procedure timetable: Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group

    EMA

    Valsartan recall: 4 things patients should know

    CNN

    Authorised products containing valsartan as active substance: Overview

    SWISSMEDIC

    Real-world data finds patients feel better on Entresto, says Novartis

    PMLIVE

    Novartis Boosts Cardiovascular Pipeline with $1bn Ionis Deal

    PMLIVE

    NICE backs restricted use of heart drug Entresto

    PHARMA TIMES

    ICER Releases Final Report on CardioMEMS HF System™ and Entresto™

    ICER-REVIEW

    Novartis heart failure medicine Entresto™ substantially cuts 30day readmissions

    PR NEWS WIRE

    Novartis` heart failure medicine Entresto recommended for EU approval

    MARKET WATCH

    Swiss giant to make key heart failure drug here

    STRAITS TIMES

    Novartis Says Swissmedic Approves Entresto In Heart Failure

    NASDAQ

    Faster track to `megablockbuster`? Novartis` Entresto already soaring on social media

    FIERCE PHARMA MARKETTING

    Is The Superiority Of Entresto Just An Illusion?

    FORBES

    Treato Finds Demand Will be High for Heart Failure Drug Entresto

    PR NEWS WIRE

    Novartis CEO: Payers not sold on performance pricing yet, but that`ll change

    FIERCE PHARMA

    Novartis to start human tests with Google lens in 2016

    THE ECONOMIC TIMES

    Lcz696 targets blood pressure and arterial stiffness

    SCIENCE DAILY

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.